香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責 任。 有關潛在加密貨幣購買的購買授權 茲提述本公司於2025年8月8日 之 有 關，其 中 包 括，本 公 司 擬 購 買 加 密 貨 幣 的 自 願 性 公 告。由 於 董 事 會 認 為 購 買 和 持 有 加 密 貨 幣 是 本 集 團 夯 實 以 太 坊（ETH） 儲備金庫及加速ivd.xyz交 易 所 生 態 構 建 等 業 務 佈 局 和 發 展 的 重 要 舉 措，亦 是 本 集 團 資 產 配 置 策 略 的 重 要 組 成 部 分，經 審 慎 考 量 後，董 事 會 建 議 尋 求 股 東 事 先 批 准 授 出 購 買 授 權，以 授 權 董 事 會 於 股 東 特 別 大 會 上 正 式 通 過 有 關 購買授權及潛在加密貨幣購買的普通決議案當日起計36個月期間內進行潛 在 加 密 貨 幣 購 買，惟 購 買 總 金 額 不 超 過 ...

经营范围含许可项目：医疗服务（依法须经批准的项目，经相关部门批准后方可开展经营活动，具体经 营项目以审批结果为准）第一类医疗器械销售；第二类医疗器械销售；第一类医疗设备租赁；第二类医 疗设备租赁；企业管理咨询；以自有资金从事投资活动；信息咨询服务（不含许可类信息咨询服务）； 科技推广和应用服务；数字技术服务（除依法须经批准的项目外，凭营业执照依法自主开展经营活动） 企业名称华检医疗（江苏）有限公司法定代表人冯小敏注册资本1000万人民币国标行业卫生和社会工作 >卫生>医院地址南京市建邺区乐山路190号15层企业类型有限责任公司（非自然人投资或控股的法人独 资）营业期限2025-8-12至无固定期限登记机关南京市建邺区市场监督管理局 天眼查显示，近日，华检医疗（江苏）有限公司成立，法定代表人为冯小敏，注册资本1000万人民币， 由华检企业管理（深圳）有限公司全资持股。 序号股东名称持股比例1华检企业管理（深圳）有限公司100% 来源：金融界 ...

作者 | 医药多巴胺 数据支持 | 勾股大数 据（www.gogudata.com） 近期，一家港股 IVD龙头华检医疗(01931.HK)走出了数倍上涨行情，在整个医疗板块中涨势遥遥领先。 从 7月开启升势以来，公司股价7月单月涨幅约120%，8月继续向上势头，截至8月12日公司单月累计涨幅超 91 % ，市值突破 15 0 亿港 元。 至于引爆这一轮行情的核心逻辑，和华检医疗密集发布颇具颠覆性的战略举措有关。 从最新动态来看， 8月8日，公司连发三则公告，其中，自愿性公告重点提到公司启动以太坊金库战略，包括两大核心框架支撑：一方面建立 以太坊(ETH)金库储备，通过多维度资金来源，采取定投式策略持续增持以太坊；另一方面建立以太坊创造引擎（ ivd.xyz交易所 ），采取 NewCo模式，借助平台和Web3技术发力医疗创新药资产代币化领域。 与此同时，公司首批完成了 5190枚以太坊的买入， 随着 以太坊价格 突破 43 00 美元， 该批 成本价 3 661 美元的 以太坊 已经 实现 浮盈 约 330 万 美元 。 目前 ， 华检医疗 的 以太坊 储备规模在港股上市公司中排在首位 ， 考虑 到 其 董事 ...

Group 1: Hong Kong Stock Market Performance - Zhengda Enterprise International (03839) surged over 20% after reporting a revenue of approximately $323 million, a year-on-year increase of 199.44%, and a net profit attributable to shareholders of $17.046 million, up 768.36% [2] - Zhenjiu Lidu (06979) rose over 11% as research indicated that the liquor industry is moving towards a performance bottom, with expectations for a trend reversal in stock prices ahead of demand recovery [2] - Lithium stocks fell, with Tianqi Lithium (09696) down over 7.5% and Ganfeng Lithium (01772) down over 5.7%, due to anticipated long-term production halts affecting domestic lithium carbonate output by nearly 12% [2] - China General Nuclear Power (01816) increased over 3% as it plans to commission multiple nuclear units between 2025 and 2030, with expectations of a long-term price rebound in the Guangdong region [2] Group 2: Company Earnings Reports - Hillstone Technology (01478) reported a revenue of 8.832 billion RMB for the first half of the year, a year-on-year increase of 15.1%, and a net profit of 308 million RMB, up 167.6% [4] - Jinsongzi (06896) fell nearly 20% after issuing a profit warning, expecting a profit decrease of about 37% compared to the same period in 2024 [4] - Jinke Services (09666) rose over 7% after announcing an expected net profit of approximately 0 to 100 million RMB for the six months ending June 30, 2025, compared to a net loss of 194.4 million RMB in the same period last year [4] - Jingtai Holdings (02228) increased nearly 5%, forecasting a comprehensive income of no less than 500 million RMB for the first half of 2025, a year-on-year increase of at least 387% [4] Group 3: U.S. Stock Market Highlights - AMD (AMD.US) fell 0.28% after confirming it received preliminary approval for AI chip exports to China [6] - TSMC (TSM.US) rose 0.11% with July sales reaching approximately $10.806 billion, a year-on-year increase of 25.8% [6] - Micron Technology (MU.US) increased by 4.06% after raising its revenue guidance for Q4 2025 to $11.1 billion to $11.3 billion, citing improved DRAM pricing conditions [6] - Intel (INTC.US) rose 3.51% amid news of CEO Pat Gelsinger's planned discussions with the White House [7] Group 4: Emerging Companies and Innovations - Tesla (TSLA.US) rose 2.85% after applying for a power supply license in the UK, aiming to compete with local energy giants [8] - Bilibili (BILI.US) increased by 1.67%, with a report highlighting that 70% of China's Z+ generation are users of the platform, indicating strong user engagement [8] - XPeng Motors (XPEV.US) continued to rise by 5.84% as its new extended-range model entered the new vehicle announcement list, indicating an upcoming launch [8]

Core Viewpoint - The recent significant stock price increase of Huajian Medical (01931.HK) is closely linked to its strategic initiatives, including plans for dual primary listing on NASDAQ and the introduction of innovative financial products in the medical sector [1][2]. Group 1: Stock Price Volatility Drivers - The stock price of Huajian Medical has seen a cumulative increase of approximately 120% in July and an additional 62% since August, with a single-day increase of 38.43% on August 6, leading to a market capitalization exceeding 12.8 billion HKD [1][2]. - Key strategic announcements include the initiation of a dual primary listing plan on NASDAQ on July 14, aimed at expanding the international shareholder base and enhancing participation in global capital markets [2]. - The launch of the medical innovation drug RWA Exchange and the associated stablecoin IVDDollar on July 17 addresses issues of liquidity and financing cycles in the medical sector, attracting market attention [2]. - Establishment of a wholly-owned subsidiary, IVD GROUP INC., in New York and submission of stablecoin license applications to SEC and CFTC on July 20, positioning the company as a rare player in the Hong Kong market with dual stablecoin licensing [2]. Group 2: Ethereum Vault Strategy - On August 8, the company announced the initiation of its Ethereum Vault strategy, including the purchase of 5,190 Ether, marking the largest reserve among Hong Kong-listed companies [3]. - The Ethereum Vault strategy consists of two main components: the Ether reserve and the Ether creation engine (medical RWA), utilizing blockchain technology for the tokenization of medical assets [3][10]. - The strategy is compared to successful U.S. companies like MicroStrategy and Summit Therapeutics, indicating potential for significant value growth if market recognition continues [4]. Group 3: Market Context and Competitive Landscape - The U.S. regulatory environment for cryptocurrencies is becoming clearer, providing a stable policy outlook for Ethereum and decentralized finance (DeFi) applications, which enhances the intrinsic value of Ether as a core reserve asset [5]. - Companies like MicroStrategy have successfully integrated cryptocurrency reserves into their capital operations, achieving substantial market capitalization growth, which serves as a model for Huajian Medical [6]. - The Ethereum Vault strategy of Huajian Medical is noted for its unique approach, focusing on long-term, stable asset reserves through diversified funding sources, contrasting with other companies' strategies [9][10]. Group 4: Medical RWA Platform Development - Huajian Medical's extensive experience in the medical field, with over 20 years of operation and a network covering 1,674 tertiary hospitals in China, supports the establishment of its medical RWA platform [11]. - The company's proactive compliance strategy, including early license application disclosures and establishment of a subsidiary in New York, positions it favorably in the evolving global regulatory landscape [11]. - The integration of traditional medical assets with blockchain finance through the medical RWA platform addresses funding efficiency issues in the medical innovation sector, a relatively rare model in the Hong Kong market [12].

发布会将重磅发布华检医疗"全球增强版以太坊(ETH)金库"的升级内容。通过整合HashKey集团的技术 与合规优势，该战略将构建更安全、高效、合规的数字资产服务体系，为全球投资者提供创新的资产配 置路径，助力医疗创新药知识产权的全球化流通。 3、行业领袖共襄盛举 活动将邀请监管机构代表、顶尖机构投资者、医疗与区块链领域专家及权威媒体出席，共同见证这一里 程碑事件。华检医疗与HashKey集团高层将深度解读合作愿景，阐述如何通过技术赋能实体经济，重塑 医疗健康产业的金融生态。 强强联合，开启Web3医疗金融新篇章 华检医疗控股有限公司(01931)8月8日公告宣布，集团正式启动"全球增强版以太坊(ETH)金库"战略，并 与HashKey集团达成全球战略合作。公告同时宣布，华检医疗将于8月11日下午14:00在香港中环交易广 场3期14楼HashKey公司隆重举行"全球战略合作签约仪式暨华检医疗全球增强版以太坊(ETH)金库战略 升级发布会"。 此次发布会标志着华检医疗与HashKey集团在Web3链上金融领域的深度布局正式启动，双方将携手探 索数字资产与实体经济融合的创新路径，为全球医疗健康产业注入新动能。 发 ...

Group 1 - The cryptocurrency ETF and related stocks have shown strong performance, with notable increases in share prices for companies such as Huajian Medical (up 18.75% to HKD 9.31), Mistrategy (up 16.95% to HKD 4.14), and others [1] - Bitcoin has surpassed the USD 120,000 mark, reaching a new high since July 18, with Ethereum also breaking the USD 4,300 barrier, marking its highest price since 2021 [1] - Analysts attribute the recent surge in cryptocurrency prices to a weakening confidence in the US dollar, although there are concerns about accumulating risks, particularly from high-leverage trading leading to a wave of liquidations [1] Group 2 - President Trump has signed an executive order allowing private equity funds, real estate, cryptocurrencies, and other alternative assets to be included in 401(K) retirement accounts, which traditionally focused on safer investments like mutual funds and bonds [1]

另外，华检医疗还称，经董事会决议通过，公司已于近日与全球领先的数字资产金融服务集团HashKey Group签订了全球战略合作框架协议，旨在通过双方的紧密合作，加速集团"全球增强版以太坊(ETH)金 库"战略的落地实施，并为双方的全球客户提供更加高效、安全、合规的数字资产服务。 格隆汇8月11日｜延续近期强势，华检医疗(1931.HK)今日再度走高，盘初一度飙升近27%，至9.95港 元，股价再创历史新高，该股7月中旬启动上涨行情，在7月份累涨120%后，8月份股价再度翻倍。 消息面上，港股增强版以太坊金库公司横空出世。华检医疗发布公告称，其已正式启动"具备下行保护 机制的全球增强版以太坊财库"战略。基于战略布局需要，将以太坊作为核心储备资产，目标成为港股 市场乃至全球以太坊储备规模领先之上市公司。集团将以自有资金、稳定的年度可分配利润、现有低效 库存资产置换及ATM(At-The-Market)持续融资等多维度资金来源，采取"定投式"策略持续增持以太坊。 今日加密货币价格集体走强，比特币再度升破12.1万美元/枚；以太坊突破4300美元/枚，创2021年底来 新高。 ...

华检医疗(01931)早盘涨超20%，盘中高见9.48港元再创新高，截至发稿，涨15.05%，报9.02港元，成交 额794万港元。 消息面上，华检医疗发布公告，经董事会决议通过，本公司已于近日，与全球领先的数字资产金融服务 集团HashKey Group(HashKey集团)签订了全球战略合作框架协议(框架协议)，旨在通过双方的紧密合 作，加速本集团"全球增强版以太坊(ETH)金库"战略的落地实施，并为双方的全球客户提供更加高效、 安全、合规的数字资产服务。 根据框架协议，并在遵守适用法律法规及香港联合交易所有限公司证券上市规则的前提下，此次合作将 充分利用HashKey集团的全牌照合规生态体系，为本集团提供一站式的数字资产管理服务，包括但不限 于以太坊(ETH)的大宗交易执行与成本优化、全球市场流动性支持，以及探索加密资产储备与实体经济 资产(特别是医疗创新药知识产权RWA)的融合路径。 通过与HashKey集团的合作，本集团将能够更高效地管理以太坊(ETH)储备，优化交易成本，并在全球 范围内获取更广泛的市场资源与技术支持。 ...

华检医疗（01931.HK）近期在港股市场表现活跃，股价呈现显著上升态势。7月累计涨幅约120%，8月至今再劲升约62%，其中8月6日单日涨幅38.43%，市 值突破128亿港元。这一股价变动或与公司近期一系列战略布局存在密切关联性。 一、详解公司股价波动的核心驱动因素 华检医疗股价的持续波动，受到多重因素共振影响。7月以来，公司多项战略举措相继公布： 7月14日，公司宣布启动纳斯达克双重主要上市计划，此举旨在拓展国际股东基础，提升全球资本市场参与度，相关信息公开后获得市场关注。 7月17日，华检医疗推出医疗创新药RWA交易所生态 IVDNewCo Exchange及配套稳定币 IVDDollar（IVDD）。该模式试图解决医疗创新药资产流动性不 足、融资周期较长等问题，通过将医疗IP转化为碎片化RWA代币，探索医疗资产数字化交易路径，这一业务创新开始引发市场关注和讨论。 7月20日，公司在纽约设立全资子公司 IVD GROUP INC.，并向 SEC、CFTC 提交稳定币牌照申请，进一步完善全球合规布局。在美国稳定币监管框架逐步 清晰及香港《稳定币条例》8月1日实施的背景下，华检医疗成为港股中少数同时布局美 ...